By leveraging the ASX share market and compounding, Aussie retirees can build significant cash flow in retirement.

Whether it’s $10,000 or $110,000, stocks can generate dividends to help cover certain expenses.

That cash flow doesn’t just appear out of nowhere, of course. Aussies need to invest money in assets that pay dividends.

By investing regularly, investors can build a strong portfolio.

I’m going to run through some examples of what happens when you regularly invest. For plenty of people, just the regular superannuation contributions could help reach particular portfolio value goals.

How to create $110,000 of passive income at 65 and retire

I think it’s essential for investors to think long-term. By investing regularly over many years, investors can build substantial wealth.

In retirement circles, many assume 4% is a sufficient withdrawal rate. Let’s assume someone is targeting $110,000 per year at a 4% yield, which means targeting a portfolio of $2.75 million.

That’s a big target, but I’ll show you how many Aussies can reach that goal if given long enough. In all of the below examples, I’m going to assume that the share market returns an average of 10% per year.

Imagine someone is 25, starting with $0. If they invest just $450 per month over 40 years, they would reach $2.85 million.

If someone is starting at 35 with $0, and they invest $1,250 per month over 30 years, it would become worth $2.825 million.

Starting at 45 with $0, someone could invest $3,700 per month over 20 years, it would be worth $2.81 million.

Of course, there’s a million different scenarios we could play out, but those three above situations show how investors can build towards approximately $2.75 million.

Numerous investment opportunities for dividends

There are a number of ways investors can get to $2.75 million and retire.

We could invest in the best options for long-term growth, then switch to passive income ideas. Quality ASX growth shares and exchange-traded funds (ETFs) could be strong options for wealth creation.

I think investment ideas like Vanguard MSCI Index International Shares ETF (ASX: VGS) and Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) are excellent long-term compounders.

After that I’d look at compelling ASX dividend share options.

Diversified listed investment companies (LICs) are compelling ideas such as Argo Investments Ltd (ASX: ARG), Australian United Investment Company Ltd (ASX: AUI), L1 Long Short Fund Ltd (ASX: LSF) and WCM Global Growth Ltd (ASX: WQG) are all compelling options for passive income.

I’d also be very willing to invest in cheap real estate investment trusts (REITs) offering large distribution yields, such as Centuria Industrial REIT (ASX: CIP), Dexus Industria REIT (ASX: DXI), Charter Hall Long WALE REIT (ASX: CLW) and Rural Funds Group (ASX: RFF).

I think diversification during retirement is an important factor to protect capital over the long-term.

The post How much do I need to retire on $110,000 a year at 65? appeared first on The Motley Fool Australia.

More reading

• VGS vs IVV: Which ETF would I buy with $10,000?
• Where I’d invest in ASX shares after the recent RBA rate rise
• 2 very cheap ASX shares near 52-week lows I’d buy today
• I’d buy 37,648 shares of this ASX stock to aim for $800 a month of passive income
• Is this the ASX’s perfect dividend stock?

Motley Fool contributor Tristan Harrison has positions in L1 Long Short Fund, Rural Funds Group, Washington H. Soul Pattinson and Company Limited, and Wcm Global Growth. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has positions in and has recommended Rural Funds Group and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Electro Optic Systems Holdings Ltd (ASX: EOS) shares have been among the ASX’s best performers over the past few years.

Much of the interest has come from the company’s growing order book and its push into high-energy laser weapons.

But another part of the EOS story is starting to catch my interest.

Europe.

The region is spending huge amounts of money rebuilding its defence capabilities, and EOS has been quietly putting itself in a better position to benefit.

So, could Europe become the company’s next major growth market?

Let’s take a closer look.

Europe is spending big on defence

There’s certainly no shortage of money being thrown at defence across Europe right now.

Last year, European NATO members and Canada increased defence spending by nearly 20%, or more than US$139 billion.

And that looks set to continue.

NATO members have committed to spending 5% of GDP on defence and security-related investment by 2035.

This includes at least 3.5% of GDP on core defence requirements.

Already, European members and Canada are spending close to 4% of GDP on defence and security.

There is plenty happening at the European Union level as well.

Its Readiness 2030 plan aims to mobilise up to 800 billion euros in additional defence spending.

This includes 150 billion euros to support joint procurement between member states.

Drones are also high on the shopping list.

The European Commission has launched a European Drone Defence Initiative to help strengthen the region’s defence capabilities by 2030.

EOS is building its European presence

One of the biggest changes came through EOS’ acquisition of MARSS earlier this year.

EOS completed its acquisition of the European defence technology company in May for around $134 million.

MARSS is behind NiDAR, a command-and-control platform designed to detect, track, and respond to threats such as drones.

The company has since relocated MARSS’ headquarters to Nice, France, giving EOS a bigger base in the region.

EOS also plans to expand its European operations from the site over the next three years.

And there are already signs that NiDAR is gaining traction.

BAE Systems selected the platform last year as the command-and-control system for its Battlespace Integrated Targeting System.

Could Europe drive the next leg of growth?

I think Europe could become a much bigger market for EOS over the next few years.

The company now has a bigger footprint in the region at a time when defence spending is climbing quickly.

Drones are also becoming a much bigger focus, which plays nicely into what EOS is already doing.

And with billions of dollars set to be spent on defence across Europe, there should be plenty of opportunities ahead.

The post Could Europe become the next big market for EOS? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• EOS shares jump 7% as ASX 200 falls. Could $15 be next?
• Electro Optic Systems vs Droneshield: Which ASX defence share wins?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Electro Optic Systems. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced the US FDA has granted Fast Track designation for its BiPASS program, which targets earlier and less invasive prostate cancer diagnosis.

What did Telix Pharmaceuticals report?

• Received FDA Fast Track designation for BiPASS, a pre-biopsy prostate cancer imaging program.
• BiPASS evaluates gallium-68 PSMA-PET imaging alongside MRI to guide prostate cancer diagnosis before biopsy.
• Completed Phase 3 patient enrollment for BiPASS, using Illuccix and Gozellix agents.
• Engaged positively with FDA, planning for a new drug application (NDA) to expand access to this imaging method.
• Clinical data shows combining PSMA-PET and MRI can reduce unnecessary biopsies by nearly 50%.

What else do investors need to know?

Telix Pharmaceuticals’ BiPASS program aims to address a significant unmet need. Currently, over three million prostate biopsies are performed worldwide each year, but up to 75% yield negative results, making many procedures unnecessary and stressful for patients.

The FDA’s Fast Track designation means Telix can engage with the regulator more frequently and could have its submission for approval reviewed more quickly. If approved, the BiPASS approach may broaden the use of advanced imaging in prostate cancer care.

In addition, the company’s commercial products, Illuccix and Gozellix, are already approved in multiple global markets for imaging PSMA-positive prostate cancer. However, their use in pre-biopsy diagnosis remains investigational.

What did Telix Pharmaceuticals management say?

Dr. David N. Cade, Group Chief Medical Officer at Telix, said:

Fast Track designation reflects the FDA’s recognition of the potential for BiPASS to address an important unmet need in the prostate cancer diagnostic pathway. We believe gallium-68 PSMA-PET, used alongside MRI, could help physicians make more informed decisions before biopsy, improve diagnostic confidence and potentially reduce unnecessary invasive procedures for patients. This designation supports continued close engagement with the FDA as we advance BiPASS toward an NDA submission.

What’s next for Telix Pharmaceuticals?

Telix plans to submit a new drug application (NDA) for BiPASS to the FDA, seeking approval for use before invasive prostate biopsies. If successful, this could open up a larger market and provide faster, less stressful diagnostic options for many patients.

The business continues to build on a broad pipeline, with late-stage programmes for prostate, brain, and kidney cancers, and aims to establish further growth in international markets.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, the Telix Pharmaceuticals share price has risen 11%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.

View Original Announcement

The post Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Telix Pharmaceuticals, Qualitas, Greatland Resources shares
• These are the 10 most shorted ASX shares
• 2 ASX shares UBS says could increase 13% to 37%
• 5 ASX 200 shares upgraded by experts this week
• Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.